Alzamend Neuro Files 8-K
Ticker: ALZN · Form: 8-K · Filed: May 22, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $2.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Alzamend Neuro filed an 8-K on 5/22/24 covering Reg FD and financials.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on May 22, 2024, reporting on Regulation FD disclosures and financial statements. The company, incorporated in Delaware, has its principal executive offices in Atlanta, GA.
Why It Matters
This filing provides important updates on Alzamend Neuro's regulatory disclosures and financial status, which are crucial for investors to assess the company's performance and compliance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- May 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Atlanta, GA (location) — Address of principal executive offices
- 001-40483 (company_id) — Commission File Number
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 22, 2024.
In which state was Alzamend Neuro, Inc. incorporated?
Alzamend Neuro, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office is located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
What is Alzamend Neuro, Inc.'s telephone number?
Alzamend Neuro, Inc.'s telephone number is (844) 722-6333.
Filing Stats: 869 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-05-22 16:30:23
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
- $2.5 million — requires stockholder equity of at least $2.5 million (or an alternative listing standard), a
Filing Documents
- p5212408k.htm (8-K) — 28KB
- ex99_1.htm (EX-99.1) — 7KB
- alzamendlogo_med.jpg (GRAPHIC) — 24KB
- 0001214659-24-009785.txt ( ) — 243KB
- alzn-20240522.xsd (EX-101.SCH) — 3KB
- alzn-20240522_lab.xml (EX-101.LAB) — 33KB
- alzn-20240522_pre.xml (EX-101.PRE) — 22KB
- p5212408k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure As previously reported under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing), on March 26, 2024, Alzamend Neuro, Inc. (the " Company ") was notified by the Listing Qualifications Staff (the " Staff ") of the Nasdaq Stock Market, LLC (" Nasdaq ") that it had not regained compliance with Nasdaq Listing Rule 5550(b)(2). As a result, unless the Company requested an appeal of this determination, the Staff has determined that the Company's common stock would be delisted from The Nasdaq Capital Market. The Company requested an appeal of the Staff's determination to a Hearings Panel (the " Panel "). The Panel heard the Company's appeal on May 9, 2024. On May 21, 2024, the Company received notice from the Panel that it granted the Company's request to continue its listing on Nasdaq, subject to the Company demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550(b)(1), which requires stockholder equity of at least $2.5 million (or an alternative listing standard), and satisfying all applicable requirements for continued listing on Nasdaq. On May 22, 2024, the Company issued a press release to announce the Panel's decision. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under this item shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. The Securities and Exchange Commission encourages registrants to disclose
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release dated May 22, 2024 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: May 24, 2024 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel 3